Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

• Ages 50 years and older
• All sexes
• No healthy volunteers
• Adult, Older adult

Trial locations and contacts

1 site in 1 country.

About this study

Official title: An Open-Label Study of Aripiprazole to Evaluate the Safety and Tolerability in Patients With Psychosis Associated With Parkinson's Disease

Conditions

Parkinson's Disease, Psychoses

Being tested

aripiprazole

Keywords

Psychosis, Parkinson's Disease

Medical subject headings

Parkinson Disease, Psychotic Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

• aripiprazoleDrug

  Also called Abilify

  Tablets, Oral, 1-10mg, Once daily, 6 weeks.

What is being measured

The primary outcome is the main question the study is designed to answer.

1. Tolerability

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1. First posted9 Nov 2004 (estimated)
2. Study startJul 2003
3. Primary completionSep 2004
4. Study completionSep 2004

Resources

• Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
• Publications (1)Papers the sponsor has linked to this study.
• Other trials for Parkinson's DiseaseStudies of the same condition, open and under way.
• More trials run by Otsuka Pharmaceutical Development & Commercialization, Inc.The sponsor's other registered studies.
• What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.